Omeros (NASDAQ:OMER) CAO David Borges Sells 10,000 Shares of Company Stock

Omeros Corporation (NASDAQ:OMER) CAO David Borges sold 10,000 shares of Omeros stock in a transaction that occurred on Wednesday, September 23rd. The stock was sold at an average price of $20.95, for a total transaction of $209,500.00. Following the completion of the sale, the chief accounting officer directly owned 5,000 shares of the company’s stock, valued at approximately $104,750. This trade represents a 66.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Omeros Stock Down 0.2%

NASDAQ:OMER traded down $0.05 during mid-day trading on Tuesday, reaching $19.39. The company’s stock had a trading volume of 387,803 shares, compared to its average volume of 1,687,194. Omeros Corporation has a 1 year low of $4.05 and a 1 year high of $21.24. The firm has a market capitalization of $1.40 billion, a PE ratio of 15.15 and a beta of 2.60. The stock has a fifty day moving average of $16.40 and a 200-day moving average of $13.11.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.27) by $0.29. The company had revenue of $28.53 million for the quarter, compared to analysts’ expectations of $12.69 million. On average, analysts expect that Omeros Corporation will post -0.37 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of OMER. Dimensional Fund Advisors LP lifted its holdings in Omeros by 85.2% in the first quarter. Dimensional Fund Advisors LP now owns 179,594 shares of the biopharmaceutical company’s stock valued at $1,897,000 after acquiring an additional 82,646 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Omeros during the 2nd quarter worth $57,484,000. Bank of America Corp DE increased its position in Omeros by 57.8% during the 1st quarter. Bank of America Corp DE now owns 204,805 shares of the biopharmaceutical company’s stock worth $2,163,000 after purchasing an additional 74,997 shares in the last quarter. Corient Private Wealth LP purchased a new stake in shares of Omeros during the second quarter worth about $6,274,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Omeros in the 2nd quarter worth about $1,864,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Weiss Ratings downgraded Omeros from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, September 22nd. Cantor Fitzgerald upgraded Omeros from a “neutral” rating to an “overweight” rating and set a $22.00 price objective on the stock in a research report on Tuesday, September 22nd. Zacks Research lowered shares of Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Finally, Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $34.00.

About Omeros

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.